'Ecog ps' presentation slideshows

Novel Targets and Therapies for GI Malignancies: What does the future hold?

Novel Targets and Therapies for GI Malignancies: What does the future hold?. David H. Ilson, M.D., Ph.D. GI Oncology Service Memorial Sloan-Kettering Cancer Center New York, NY. GI Cancers: US Incidence in 2013. 292,200 new cases and 144,570 deaths (49%) Case Fatality Rate:

942 views • 71 slides

Department of Thoracic Oncology

Filippo de Marinis Department of Thoracic Oncology, IEO, Milan, Italy. Department of Thoracic Oncology. LIFE STUDY 2nd Line TREATMENT. 13%. 52%. 34.0%. C Gridelli, F de Marinis et al, data on file, 2013. ESMO GL WG, Ann Oncol 2012.

640 views • 42 slides

421 views • 41 slides

PLASMA CELL DYSCRASIAS

CLASSIFICATION. Monoclonal gammopathy of uncertain significance (MGUS) Idiopathic Associated with other diseases (autoimmune, infectious, non-heme cancer, etc) Plasma cell or lymphoid malignancy Waldenstrom's macroglobulinemia Other lymphoproliferative disorders Smoldering multiple myeloma

3.41k views • 40 slides

New Hormonal Therapies Roberto Iacovelli

The New era of CRPC: few targets for a pletora of agents!. Cabazitaxel. Sipuleucel-T. Alpharadin. ADT. Docetaxel. PD. PD. Abiraterone. MDV3100. Legend:. Hormonal therapy. Chemotherapy. TAK700. Radiometabolic therapy. Immunotherapy. New Hormonal Therapies Roberto Iacovelli.

606 views • 38 slides

Eric Van Cutsem*, M Nowacki, I Lang, S Cascinu, I Shchepotin, J Maurel,

494 views • 24 slides

Background

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic) Ethan M. Basch (Memorial Sloan-Kettering) Jeff A. Sloan (Mayo Clinic) Additional Collaborators:

477 views • 20 slides